4Q11 US Copaxone sales were ~$740M, although the number was not explicitly disclosed by Teva. This estimate is based on: i) the disclosed $1.0B of 4Q11 worldwide Copaxone sales; ii) the 74% share of worldwide Copaxone sales in the US market during 3Q11; and iii) the lack of pricing pressure for Copaxone in the US market, according to Teva.
The $740M estimate above is consistent with Teva’s guidance for the full year 2012, which implies about $2.8B of US Copaxone sales (#msg-70158971). Teva’s 2012 sales guidance excludes the launch of a generic, of course.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.